Now showing items 1-2 of 2

    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 

      Tutt, A; Tovey, H; Cheang, MCU; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, JM; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, MQ; Hoadley, KA; Parikh, J; Parker, P; Perou, CM; Roylance, R; Shah, V; Shaw, A; Smith, IE; Timms, KM; Wardley, AM; Wilson, G; Gillett, C; Lanchbury, JS; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, SE; Bliss, JM (2018-05)
      Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs ...
    • International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. 

      Scott, AJ; Alexander, JL; Merrifield, CA; Cunningham, D; Jobin, C; Brown, R; Alverdy, J; O'Keefe, SJ; Gaskins, HR; Teare, J; Yu, J; Hughes, DJ; Verstraelen, H; Burton, J; O'Toole, PW; Rosenberg, DW; Marchesi, JR; Kinross, JM (2019-09)
      Objective In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution of the human microbiome to carcinogenesis. Design International experts in oncology ...